Is the Availability of Biosimilar Adalimumab Associated with Budget Savings? A Difference-in-Difference Analysis of 14 Countries

ConclusionThe availability of biosimilars was associated with a decrease in adalimumab expenditure without compromising the consumption of adalimumab.
Source: BioDrugs - Category: Drugs & Pharmacology Source Type: research